by Dan Roberts A couple of changes are on the horizon which may allow visually impaired people to regain or maintain the pleasure of piloting their own private vehicles whenever and wherever they choose. The most immediate change could come from relaxation of the minimum visual acuity requirements, made possible in part by the development of bioptic [Read More]
News
New Drug Under Study for Dry MD
Ophthotech Corporation has announced that the first patient has been dosed in a Phase 2/3 clinical study of Zimura® (avacincaptad pegol sodium) for treatment of advanced dry macular degeneration (MD). Zimura® is an inhibitor of complement factor C5, a central component of the complement cascade believed to be involved in the development of AMD. The Company has also recently [Read More]
Let’s Be Clear About Blue Light
Editorial by Dan Roberts The media is becoming saturated with warnings about the so-called “blue light hazard”. Let’s pull it back a bit by being more specific about who should be most concerned. In 2006, I published a paper titled Artificial Lighting and the Blue Light Hazard. The purpose of the paper was to warn of [Read More]
New Study Underway for Treatment of Dry Macular Degeneration
Subjects are being sought for trials to test the new Nova Oculus™ device as the only scientifically supported treatment for dry macular degeneration. Presently, no scientifically proven treatment option is available for those with dry macular degeneration (dMD). Ongoing research, however, is showing that a new device using biocurrent technology (very low micro-current electrical stimulation) [Read More]
Glaucoma Awareness Can Help Save Your Vision
Important Information from the National Eye Institute Glaucoma is a major cause of vision loss in the U.S. While it currently affects about 3 million Americans, estimates show 6.3 million could have glaucoma by 2050. With Glaucoma Awareness Month in January, it’s a good time to think about scheduling a comprehensive dilated eye exam, especially [Read More]